# In silico design of a multiepitope subunit vaccine targeting Salmonella enterica serovar Infantis: an immunoinformatics and reverse vaccinology approach

## TL;DR

Researchers designed a potential vaccine against Salmonella Infantis using computational methods to identify and assemble immune-stimulating protein fragments.

## Contribution

A novel multiepitope subunit vaccine candidate was computationally designed and validated for Salmonella Infantis using immunoinformatics and reverse vaccinology.

## Key findings

- CsgA was identified as a conserved and immunogenic antigen in Salmonella Infantis.
- A multiepitope vaccine construct with CTB adjuvant showed stability and strong immune simulation responses.
- The vaccine candidate was codon-optimized and cloned in silico into the pET30a(+) vector for potential expression.

## Abstract

Salmonella enterica serovar Infantis is an emerging zoonotic pathogen increasingly linked to poultry and multidrug-resistant human infections. Existing vaccines lack serovar-specific efficacy, underscoring the need for targeted immunization strategies. In this study, we employed an immunoinformatics and reverse vaccinology pipeline to design a multiepitope subunit vaccine (MEV) against S. Infantis. A subtractive proteomics analysis of 692 poultry-derived genomes identified CsgA as a highly conserved, immunogenic, and non-host homologous antigen. Selected cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and B-cell epitopes were filtered for antigenicity, immunogenicity, allergenicity, and sequence conservation. The epitopes were assembled with appropriate linkers and a cholera toxin B (CTB) adjuvant. Structural modeling and normal mode analysis confirmed the construct’s stability, while molecular docking predicted high-affinity interactions with chicken TLR2, TLR5, MHC-I, and MHC-II. Immune simulations indicated robust humoral and cellular responses. Codon optimization yielded a codon adaptation index (CAI) of 1.0 and GC content of 54.76%, supporting efficient expression in E. coli. The optimized construct was successfully cloned in silico into the pET30a(+) vector. These findings present a rationally designed, computationally validated vaccine candidate with the potential to induce protective immunity against S. Infantis, warranting further experimental validation.